MA20150279A1 - (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel - Google Patents

(r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel

Info

Publication number
MA20150279A1
MA20150279A1 MA37496A MA37496A MA20150279A1 MA 20150279 A1 MA20150279 A1 MA 20150279A1 MA 37496 A MA37496 A MA 37496A MA 37496 A MA37496 A MA 37496A MA 20150279 A1 MA20150279 A1 MA 20150279A1
Authority
MA
Morocco
Prior art keywords
nifuratel
infections
synthesis
treatment
relates
Prior art date
Application number
MA37496A
Other languages
English (en)
Inventor
Stefania Gagliardi
Alessandra Consonni
Federico Mailland
Anna Bulgheroni
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47846051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA20150279(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA20150279A1 publication Critical patent/MA20150279A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/02—Preparation of hydrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention concerne le (r)-nifuratel et son utilisation comme bactéricide et agent bactériostatique ainsi que des compositions pharmaceutiques le contenant; de manière inattendue, le (r)-nifuratel s'est avéré présenter un meilleur profil antimicrobien que le nifuratel racémique ou le (s)-nifuratel. La présente invention concerne également une nouvelle procédure de synthèse du (r)-nifuratel et du (s)-nifuratel.
MA37496A 2012-05-11 2013-03-13 (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel MA20150279A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20120167640 EP2662371A1 (fr) 2012-05-11 2012-05-11 (R)-nifuratel et synthèse de (R) et (S)-nifuratel
PCT/EP2013/055078 WO2013167295A1 (fr) 2012-05-11 2013-03-13 (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel

Publications (1)

Publication Number Publication Date
MA20150279A1 true MA20150279A1 (fr) 2015-08-31

Family

ID=47846051

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37496A MA20150279A1 (fr) 2012-05-11 2013-03-13 (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel

Country Status (27)

Country Link
US (2) US9284306B2 (fr)
EP (2) EP2662371A1 (fr)
JP (1) JP2015515998A (fr)
KR (1) KR20150008871A (fr)
CN (1) CN104379580A (fr)
AU (1) AU2013258385A1 (fr)
BR (1) BR112014027953A2 (fr)
CA (1) CA2869827A1 (fr)
CL (1) CL2014002951A1 (fr)
CO (1) CO7131368A2 (fr)
CR (1) CR20140505A (fr)
DO (1) DOP2014000252A (fr)
EA (1) EA201492081A1 (fr)
EC (1) ECSP14026432A (fr)
GE (2) GEP201706626B (fr)
HK (1) HK1202539A1 (fr)
IL (1) IL235429A0 (fr)
IN (1) IN2014DN09256A (fr)
MA (1) MA20150279A1 (fr)
MX (1) MX2014013759A (fr)
NZ (1) NZ700752A (fr)
PE (1) PE20150167A1 (fr)
PH (2) PH12014502500A1 (fr)
SG (2) SG11201406447SA (fr)
TN (1) TN2014000430A1 (fr)
WO (1) WO2013167295A1 (fr)
ZA (1) ZA201407596B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108254453A (zh) * 2016-12-28 2018-07-06 苏州电器科学研究院股份有限公司 一种有效测定塑料制品中邻苯二甲酸酯含量的检测方法
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
CN108760950B (zh) * 2018-04-25 2022-07-15 国检测试控股集团京诚检测有限公司 一种测定硝基呋喃代谢物的方法
CN111892557B (zh) * 2019-05-05 2022-11-08 河北圣泰材料股份有限公司 哌嗪类成膜离子液体的合成方法
CN110672765B (zh) * 2019-10-11 2022-03-18 温州海鹤药业有限公司 一种定量检测硝呋太尔中顺式异构体杂质的方法
CN112457304B (zh) * 2020-12-07 2022-03-11 中国药科大学 一种硝呋太尔的制备方法
CN113828243B (zh) * 2021-09-14 2022-06-28 南京南大药业有限责任公司 一种硝呋太尔制霉菌素栓制造方法及设备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL120945C (fr) 1962-08-01
CN100506820C (zh) 2006-03-16 2009-07-01 韩志强 (s)-硝呋太尔,其制备方法和应用
CN100516063C (zh) * 2006-03-16 2009-07-22 韩志强 硝呋太尔的生产方法
CN101434584A (zh) * 2007-11-15 2009-05-20 中山大学 具有抗菌活性的手性噁唑烷酮类化合物
EP2243482A1 (fr) * 2009-04-20 2010-10-27 Polichem SA Utilisation de nifuratel pour traiter des infections provoquées par des espèces d'Atopobium

Also Published As

Publication number Publication date
US20150148547A1 (en) 2015-05-28
US20150119431A1 (en) 2015-04-30
TN2014000430A1 (en) 2016-03-30
CN104379580A (zh) 2015-02-25
US9284306B2 (en) 2016-03-15
JP2015515998A (ja) 2015-06-04
AU2013258385A1 (en) 2014-10-30
CR20140505A (es) 2015-02-06
GEP201706626B (en) 2017-02-10
SG11201406447SA (en) 2014-11-27
EA201492081A1 (ru) 2015-06-30
PH12014502500B1 (en) 2014-12-15
WO2013167295A1 (fr) 2013-11-14
SG10201608485XA (en) 2016-12-29
IL235429A0 (en) 2014-12-31
KR20150008871A (ko) 2015-01-23
GEP201606595B (en) 2017-01-10
CO7131368A2 (es) 2014-12-01
ZA201407596B (en) 2016-05-25
CL2014002951A1 (es) 2014-12-26
IN2014DN09256A (fr) 2015-07-10
NZ700752A (en) 2016-02-26
BR112014027953A2 (pt) 2018-02-06
DOP2014000252A (es) 2014-12-31
PH12014502500A1 (en) 2014-12-15
HK1202539A1 (en) 2015-10-02
PH12015502241A1 (en) 2016-08-15
CA2869827A1 (fr) 2013-11-14
US9067927B2 (en) 2015-06-30
ECSP14026432A (es) 2015-09-30
PE20150167A1 (es) 2015-02-07
MX2014013759A (es) 2015-08-07
EP2847189A1 (fr) 2015-03-18
EP2662371A1 (fr) 2013-11-13

Similar Documents

Publication Publication Date Title
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
TN2013000353A1 (fr) Dérivés de fluoro-pyridinone utiles comme agents antibactériens
WO2011117145A3 (fr) Inhibiteurs de pyrrolopyrazine kinase
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
MX2013005407A (es) 5-halopirazolcarboxamidas.
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA200801997A1 (ru) Новые соединения
MX2012002641A (es) Inhibidores de cinasa janus (jak).
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
EA201171210A1 (ru) Производные оксадиазола
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MA35638B1 (fr) 2-thiopyrimidinones
EA201000329A1 (ru) Циклические депсипептиды
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
IN2015DN00338A (fr)
WO2014085211A3 (fr) Sulfones spirocycliques en tant qu'inhibiteurs de gamma sécrétase
MX2014001623A (es) Uso de la cardiotofina-1 para el tratamiento de enfermedades renales.
EA201791321A1 (ru) Составы ингибитора lfa-1
FR3065009B1 (fr) Secretome bacterien pour son utilisation dans le traitement des lesions cutanees